AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 4 - (NewsRx.com & NewsRx.net) -- University of Kentucky researchers are part of a national team testing a possible vaccine for a common type of adult diabetes.
The vaccine, if successful, could eliminate or decrease the need for insulin injections among up to 25% of people with adult-onset diabetes - up to 3.2 million Americans.
The research is being done at U.K. and four other sites nationally, including St. Louis' Washington University.
"I think it would have a huge impact," said Dr. Dennis Karounos, director of the University of Kentucky's Diabetes Program and coinvestigator for the study. "The hope would be that fewer people would be dependent on insulin."
The vaccine, called DiaPep277, might a type of diabetes known as "11/2" in check by protecting insulin-producing cells of the pancreas.
The vaccine would be injected every 3-6 months.
The national trial will study the vaccine's effectiveness. If successful, it won't be widely available for at least 2 years, Karounos said. In earlier studies, the vaccine was shown to stop the progression of type 1 diabetes in animals and humans.